The three classes of receptors of opioids are Mu Kappa and Delta.

Mention the
effects exerted when each of three receptors are stimulated.
Mu:
Mu opioid receptors mediate positive reinforcement following direct (morphine) or
indirect (alcohol, cannabinoids, nicotine) activation, and our understanding of mu
receptor function is central to the development of addiction therapies. Recent data
obtained in native neurons confirm that mu receptor signaling and regulation are
strongly agonist- dependent. Current functional mapping reveals morphine-activated
neurons in the extended amygdala and early genomic approaches have identified
novel mu receptor-associated proteins. A classification of about 30 genes either
promoting or counteracting the addictive properties of morphine is proposed from
the analysis of knockout mice data. The targeting of effectors or regulatory proteins,
beyond the mu receptor itself, might provide valuable strategies to treat addictive
disorders.
Kappa:
The effects of the kappa- agonist, that were blocked by a selective kappa-antagonist,
nor- binaltorphimine, were significantly antagonized by the PKC antagonists,
staurosporine and/or chelerythrine. The results indicate that PKC mediates the
actions of kappa-receptor stimulation.
Delta:
Delta opioid receptors (DORs) are broadly expressed in the brain, and their activation
protects cells from hypoxic/ischemic insults by counteracting disruptions of ionic
homeostasis and initiating neuroprotective pathways. The DOR agonist D-Ala2-D-
Leu2-Enkephalin promotes neuronal survival, mitigates apoptotic pathways, and
protects neurons and glial cells from ischemia-induced cell death, thus making
DADLE a promising therapeutic option for stroke. The significant amount of research
regarding DORs and DADLE in the last decades also suggests their potential in
treating other neurological disorders.